ProCE Banner Activity

TRANSCEND NHL 001: R/R MCL Cohort of Phase I Study of Lisocabtagene Maraleucel

Slideset Download
Conference Coverage

CAR T-cell therapy lisocabtagene maraleucel yields ORR of 84% (CR rate of 66%) among patients with relapsed/refractory MCL with a 3% incidence of grade ≥ 3 CRS.

Released: December 08, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology